Our Take
Another incremental capacity play in a region where tax incentives, not operational advantages, drive the math.
Why it matters
Biologics manufacturing location decisions signal where companies expect regulatory and cost pressures to land over the next decade.
Do this week
Procurement teams: audit your biologics suppliers' geographic risk before Q2 planning cycles to avoid supply chain gaps.
Amgen commits another $300M to Puerto Rico operations
Amgen will invest an additional $300 million in its biologics production facility in Juncos, Puerto Rico (per Endpoints News reporting). The funding builds on the company's existing manufacturing presence in the territory, which produces biologics for the company's portfolio.
The investment comes as Novartis moves in the opposite direction in Germany, planning to exit its oral drug manufacturing facility there. These moves reflect ongoing shifts in pharmaceutical manufacturing footprints as companies balance cost structures, regulatory environments, and supply chain resilience.
Tax incentives drive Puerto Rico pharma investment
Puerto Rico offers substantial tax advantages for pharmaceutical manufacturing through its Act 60 incentives, which can reduce corporate tax rates to as low as 4%. The island hosts major operations from multiple pharma companies, making it a critical node in U.S. drug supply chains.
Amgen's additional commitment suggests confidence in the regulatory stability of these incentives. However, the concentration of manufacturing in Puerto Rico also creates supply chain vulnerabilities, as demonstrated during Hurricane Maria in 2017 when multiple facilities went offline.
Geographic concentration creates supply risks
The continuing buildup of biologics manufacturing in Puerto Rico creates both opportunities and risks for healthcare systems and biotech companies. While the tax advantages are substantial, the geographic concentration means weather events or regulatory changes can disrupt multiple supply chains simultaneously.
Companies sourcing biologics should map their suppliers' manufacturing locations and assess backup capacity. The Novartis exit from Germany also signals that traditional European manufacturing hubs face pressure from lower-cost locations with favorable regulatory frameworks.